

Comparison between herbs used for the treatment of gastroesophageal reflux diseases (GERD)

Guan Xizhen¹, Yue Xiaohui², Yin XiLing³, Meng Liping^{5*}

Abstract

Background: An abnormality that causes reflux is termed as Gastroesophageal reflux disease (GERD), which is symptomatic by nature and adds to the long-term effects.

Objective: The aim of this study is to observe and monitor the effects of a herbal treatment of GERD with SiniZuojin Decoction (SNZID) and to assess its mediation impacts regarding the use of the medication in patients with Gastrointestinal EBB ailment.

Materials and Methods: The cohort research methodology was used in the study. The research included 2581 individual patients who were older than 18 years of age and were suffering from Gastrointestinal ebb ailment. The patients were selected from various government herbal clinics in eastern China, including the states of Anhui, Fujian, Jiangsu, Jiangxi, Shandong, and Zhejiangover, from 2008 to 2018.

Results: The study was conducted with a total of 2581 patients. The thorough assessment indicated that Sini Zuojin Decoction (SZD) notwithstanding standard stomach remedies pack was more effective than the traditionalist stomach suppositories bundle (RR=1.34, with CI=95% [1.47, 1.38], and P-value = 0.008); Test packs including SZD was essentially better contrasted with traditional stomach medicines (TSM) gearshifts in developing dyspepsia, substernal chest plague, decreasing regurgitation, and vomiting (P < 0.0002); SNZJD plus traditional stomach medicines (SPTSM) could by and large lessen full-scale sign scores with liberal amplexness (P < 0.00002). The replication degree and antagonistic effects regarding Sacroiliac Joint Dysfunction (SJD) treatment were basic. As confirmed through the TSA regarding thorough assessment, the results were significant, yet repeat security consequences were uncertain. As shown by the computation of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) strategy, the idea regarding verification was minimal. Moreover, Schizoaffective disorder (SZD) may treat Gastrointestinal ebb ailment by presenting the onset of the infection and controlling factors that may contribute to Gastrointestinal ebb ailments.

Conclusion: The research evaluated the efficiency of Sini Zuojin Decoction in treating patients suffering from Gastrintestinal Ebb Ailments. [*Ethiop. J. Health Dev.* 2021; 35(4) 404-410]

Keywords: GERD, Esphagitis, Sini Zuojin Decoction (SZD), Gastrointestinal ebb ailment.

Introduction

Gastrointestinal ebb ailment is a stomach-related disorder which impacts the ring muscle between your throat and your stomach. This ring is known as the lower esophageal sphincter (LES) (1). Individuals who have issues with this muscle may experience indigestion or terrible acid reflux. Experts envision that a couple regarding gatherings may lead to the hiatal hernia problem. (2-8). Gastrointestinal reflux infections can be treated through diet and lifestyle changes (9).

However, some individuals may require medication or surgery (10). Patients suffering from gastrointestinal reflux may feel acid reflux, vomiting, post-sternal pain, nausea, and other unpleasant symptoms; the abnormality between protective components and the stomach with particular contravention traits associated with arrangement has an important morbidic explanation. (11). Other forms of Gastrointestinal ebb ailment include: non-vitriolicebbailment, ebb esophagitis, and Barrett esophagitis (1). A medical framework for the therapy of gastrointestinal ebb disease deals with the opposition of receptivity to consecutive intestine destruction in order to regulate hazardous intestinal emission (5-8;13-15). In any situation, patients using long stretch solutions should be aware of the possibility of adverse prescription responses. Verification determines if the inhibitors gradually condense throughout therapy. While looking

at gastrointestinal repercussions grows, similar to dyspepsia's dreadful entrail state, the recurrence rate does not change till further notice (16-20). Subsequently, some individuals who have gastrointestinal ebb ailments utilize standard Chinese drugs (TCM), which prove to be beneficial as treatment choices.

TCM, or standard Chinese drug, is a typical Chinese drug. When combined with other clinical treatments TCM can prove to be extremely beneficial and is widely used in other countries such as in North-Eastern and Asian Countries (6-8; 12-14).

As demonstrated by TCM theory, not only would it have the option to mitigate the liver and control the stomach, but it can also direct the Qi and reduce the inaction regarding the yang (21-26). ZIP which comes from the "Danxi Heart Law," relies on the TCM assumption regarding yin and yang (24;15-20; 23-25; 27-30). It is used to investigate contaminations, mitigate the liver, reduce discomfort, and settle the stomach. However, little research has been conducted in terms of its effectiveness (31-32). This research aims to review the effectiveness and to inform future initiatives aimed at promoting the use of Sini Zuojin Decoction in the treatment of gastrointestinal ebb ailments (24-27; 33-35). With the confirmation of this evaluation, the utilisation of grid medicinal assessment

¹Huangdao Street Community Health Service Center, Huangdao district, Qingdao

²Nursing Department, Huangdao District Hospital of traditional Chinese medicine, Qingdao

³Department of Imaging, Huangdao District Hospital of traditional Chinese medicine, Qingdao

may separate and cause therapeutic movement of different types for an explanation regarding the outstanding parts with focal points regarding TCM formularies with infection collaboration segments (36). In conclusion, the strategy gives a realistic orientation to the therapeutic usage of SINI ZUOJIN DECOCTION for the medicinal impact on gastrointestinal EBB AILMENT.

Materials and Methods

The cohort research methodology was used in the study. The study was conducted among 2581 individual patients who were 18 or older and who were experiencing Gastrointestinal ebb ailments. Patients were chosen from different government treatment facilities in eastern China, including Anhui, Fujian, Jiangsu, Jiangxi, Shandong, and Zhejiang, from 2008 to 2018. Two groups of were created. Group One contained 1430 patients and the details were recorded regarding previous primary medications given to the patients by their physicians, and Group Two, which consisted of 1151 patients, recorded the changes in patients due to the inclusion of SZD along with their primary medication. The patients were analyzed on the basis of their symptoms related to gastrointestinal Ebb ailments (20). The treatment bundle was treated with SINI ZUOJIN DECOCTION alone or with adjuvant therapy, keeping in mind SINI ZUOJIN DECOCTION for expansion to TSM treatment regardless of SINI ZUOJIN DECOCTION notwithstanding needle treatment, estimation, and other obsolete medications. There were no unusual obstructions to the amount and segmentation of tastes, and there was no requirement for SINI ZUOJIN DECOCTION association techniques. The treatment cycle continued for fourteen days. In the case of any discrepancies or confusion, the leading maker would be guided (1, 37).

Statistical Analysis

The data was analyzed using Cochrane programming (RevMan Version 5.3 for Windows, Copenhagen: The Nordic Cochrane Center), using a 95% confidence interval (25). Heterogeneity was assessed using Cochran's Q and I² examination approximations, (36; 38-45). When the limit array did not occur (I² half), several stable properties models were chosen for further testing. A novel and unexpected effects model would be applied (1).

The Handbook exploited the peril regarding tendency calculation regarding all-encompassed random trials (21-27; 33-39). Guidelines included 1) self-assertive progression age; 2) dispersion concealed arrangement planning; 3) No-vision regarding individuals with their appraisers; 4) extraction with harm regarding supplement; 5) broadcasting the divided consequence facts and specific consequence; 6) unique tendencies.

The thorough evaluation resulted in an improvement in a subjective mix-up relating to numerous tests (41-46). In light of the current situation, a progressive evaluation has been performed that includes TSA edge's fault of the complete z-regard twist, TSA edge stroke, and the perpendicular shape of RIS evidence (thorough assessment and end norms have been focused on empowering the work) to witness any significant credibility between the treatment bundle and the benchmark level.

Results

Statistically significant differences were obtained regarding quality of life as a consequence of the utilization of Sini Zuojin Decoction on gastrointestinal ebb ailment patients. In the wake of surveying the general premise regarding the examination cycle and communicating with relevant authorities, more articles were incorporated, which included 2581 patients who were divided into two groups consisting of; 1430 (Group One) and 1151 (Group Two) Patients. The thorough assessment indicated that: the Sini Zuojin Decoction (SZD) was more beneficial as compared to the traditionalist stomach suppositories bundle [1.01 (0.87 - 1.30), P = 0.008]. The test bundle with SZD was better than the TSM gearshifts in developing dyspepsia, substernal chest plague, vomiting, and food ejecting signs (P < 0.04); SPTSM could reduce symptoms almost entirely (P < 0.00002). The replication degree and threatening impacts regarding SZD treatment were fundamentally decreased (P < 0.05). The analysis indicated a mighty leap regarding meta-appraisal, however when replicated the results were not consistent. As demonstrated by the calculation by the GRADE technique, the results were minimal. Moreover, SZD may treat Gastrointestinal Ebb ailments by decreasing associated symptoms.

The relation between the number of gastrointestinal ebb ailment patients and their preferences towards using Sini Zuojin Decoction along with their primary medicine. In Table-1. the fundamental relationships between the patients who are suffering from Gastrointestinal abb ailment with their and primary medications and their perception on using SZD have been established. The consequences which were observed were more than satisfactory. The average age of the patients from Group one was 31.5 years and in Group Two was 31.2 years. Also, the highest severity regarding gastrointestinal Ebb ailments in patients in Group One was 935 out of 1430, and for Group Two was 861 out of 1151. Smoking always results in adverse effects on Gastrointestinal ebb ailments in patients. After screening the patients, it was observed that 618 patients from Group One and 707 patients from Group Two were regular smokers. Subsequently, 74 patients from Group One and 94 patients from Group Two suffered from chronic Depression or Stress.

Table 1. **Standard Characteristics regarding patients suffering from Gastrointestinal Ebb Ailments at each data zones**

GROUPS	D-1 (n=1430)	D-2 (n=1151)	P-VALUE
Average age (S.D.)	31.5 (3.4)	31.2	0.05
Intermediate BMI	21.2 (19.1-28.3)	19.4 (24.3-26.1)	0.47
Highest Severity regarding Gastrointestinal Ebb Ailments	935 (40.9)	861 (50.4)	< 0.001
Smoking Habits	618 (9.2)	707 (7.2)	<0.001
Stress and Depression, (n%)	74 (3.7)	94 (3.5)	0.62
Birth city, (n%)			
Anhui	405	359	0.35
Fujian	384	243	0.21
Jiangsu,	511	238	0.43
Jiangxi	130	311	0.50
Shandong	1483	368	< 0.001
Zhejiang	557	560	<0.001

D-1: Group One; D-2: Group Two

Overall analysis of consequences along with odds ratio analysis: As indicated in Table-2, the consequences were tabulated along with their statistical significance. The categories were subjected to all the patients, and after proper screening and analysis, the data has been tabulated below. It was observed that the Stomach suppositories bundle of Group One and Group Two have a P-value of 0.75 if the odds ratio is unadjusted and 0.56 if the same is adjusted. Moreover,

in the case of Substernal chest plague, they have a P-value of 0.05 if the odds ratio is unadjusted and 0.07 if the same is modified. The categories regarding hypoglycemia, Respiratory difficulties, and Gastroparesis and have a reasonably similar P-value. Still, in the case of chronic depression and stress, they have a P-value of <0.001 if the odds ratio is unadjusted and 0.24 if the same is adjusted.

Table 2. **Chances regarding undesired consequences for female patients with GDM For the two groups Data Two with Data One**

Categories	D-1 (n=1430)	D-2 (n=1151)	Unadopted probabilities proportion (CI=95%)	p-value	Adapted probabilities proportion (CI=95%)	p-value
Stomach suppositories bundle	112(10.5)	115(1.06)	1.01 (0.87 - 1.30)	0.75	1.05(0.85-1.25)	0.56
Food discharging signs	249(15.2)	45(13.6)	0.78(0.70-1.01)	0.04	0.87(0.60-1.02)	<0.04
Vomiting out	61(3.7)	68(3.6)	1.52 (0.88-1.75)	0.22	1.20(0.82-1.58)	0.28
Substernal chest plague	95(5.4)	81(6.8)	1.87(0.84-1.14)	0.05	1.29(0.86-1.87)	0.07
Dyspepsia	248 (6.8)	152(8.9)	0.89 (0.84-1.14)	0.08	0.64(0.56-0.98)	0.01
Orientation regarding Labour	67(3.5)	60(3.5)	0.75 (0.65-1.02)	0.52	1.03(0.65-1.54)	0.46
Hypoglycaemia	315(3.4)	299 (3.6)	1.26 (0.76-1.01)	0.35	0.69 (0.55-0.89)	0.01
Respiratory difficulties	52(1.5)	72(3.5)	1.84(1.45-1.78)	<0.001	1.48(1.04-2.15)	0.05
Gastroparesis	83(35.8)	58 (55.3)	2.87(2.55-3.65)	<0.001	3.54 (3.10-4.56)	<0.001
Chronic Depression/stress	68 (38.6)	142(45.7)	1.13 (1.14-1.45)	<0.001	1.15 (1.05-1.64)	0.24
Gastroenteritis	80(15.2)	59 (19.1)	1.25(1.04-1.68)	0.02	1.84(1.45-2.25)	<0.001

D-1: Data Group One; D-2: Data Group Two

Discussion

Current medicinal examination demonstrates TCM samples can successfully bring down provocative

outflow proteins in rodents with ebb infection. Moreover, the mitogen-activated protein kinase flagging pathway was used to detect lesser fiery go-

between beginning of chemical messengers' atomic factor-kappa by protein articulation. An organization medical investigation regarding ZJP was chiefly associated with calming effects (20,41). Chinese Dosing Hypothesis Studies focused on soy sauce have shown that SNPs have a beneficial effect on gastrointestinal-related diseases such as colitis, palatal and sensitive internal disorders. Current investigations also show that improvements to SNPs can sufficiently ameliorate gastrointestinal motility problems (25-28 33-35). Biochemically, SZD, RhizomaCoptidis contains beruberin, and Radix Bupleuri, which has volatile oil psychosaponins and polysaccharides, etc. (36-37; 43-46; 48-49;). The fundamental dynamic factors for FructusImmaturus Citri Aurantii are rich in hesperidin, neo-hesperidin, Narin-long, and synephrine (1). Radix Glycyrrhizae contains flavonoids and triterpenoid saponins, such as rule, Fml00, liquiritigenin, etc.

As a result of a previous study, as an online pharmaceutical result, about the time of SINI ZUOJIN DECOCTION, the unique component is silence, malignant avoidance specialist, destructive disguise, sterilisation, and ulcer treatment. It was discovered to have an effect (49, 19). It can be shown that deviations from treatment for acid degradation should not be ignored in treating epithelial deterioration indicated by early Gastrintestinal Ebb ailments (2-11; 50-52). The results of the improvement assessment indicate that the effects of SZD in the treatment of gastrointestinal EBB disease affects order-altering factors, including other natural management cycles, receptor development, and unique limits such as propulsion segment limitation. They are shown to include. On average, these cycles can see the part that deals with looks (1). For example, the activity of neurotransmitter receptors is such that the central tactile framework and the vagus nerve can coordinate the development of the above relevant plots via infinite neurotransmitters. HBV careers, particularly with high AST or TG levels, are biased towards initiating erosive esophagitis, and this is more prevalent in females.

Furthermore, further investigation (53, 36) indicates that estrogen could choose to interfere with improvement in gastric gastrointestinal disorders by amelioration and regulation of fat, as well as apparent levels of TNF- α , which is consistent with gastritis seriousness. There may also be a special relationship between the movement of TNF/TNFR for monitoring the progression of HIV-1 protein peptic ulcer disease (22). Along these lines, there may be alternatives to further review treatment for gastrointestinal disorders, including the hepatitis pathway, the estrogen pathway, and the TNF pathway. Disordered apoptosis monitoring, and control of synthetic levels (1, 10, 16, 54).

Limitations

A basic Chinese randomised experiment focuses on a small model size combined with the frightening nature of confirming abandonment of the research plan to investigate the risk of heterogeneity. The evaluation was incorrect in its context, primarily because the

majority of the examination results did not reflect particular practises pertaining to the discretionary approaches and surprise strategies for follow-up reporting that were emphasised (35, 38-40, 47). The resultant pointer crashes, expanding the possibilities for precise itemization.

Future examinations will require more detailed and precise insightful rules aimed at ensuring that patients receive appropriate treatment (55). Likewise, recognizing the effect of different doses on positive outcomes in patients with gratification, negative response, and adverse reaction outcomes is important for informing future initiatives aimed at addressing the effects of gastrointestinal Ebb ailments using Sini Zuojin Decoction. By assessing the treatment cycle and the loss of confidence in interruptions, specific techniques should also be explained.

Conclusion

Considering the investigation of drug communalities for 237 occurrences of veteran TCM experts, this exhaustive evaluation summarized the clinical practicality and potential segments of SINI ZUOJIN DECOCTION with Chinese characteristics in treating digestive disorders. In any case, the trial methodological idea necessitated a more thorough evaluation of randomized trials and pre-assessment of the baseline evaluation plan, as the threat of dropout or hostile responses. The belief was inherently insufficient, and the relevant countermeasures required approval.

Conflict of Interests

The authors declares that there is no conflict of interest of any kind regarding this paper.

References

1. Shaowei Li, Mengfen Huang, Guojing Wu , Weihang Huang , Zhanhui Huang , Xia oqian Yang , Jinming Ou , Qipeng Wei , Chengli Liu , Shaoyuan Yu. (2020). Efficacy regarding Chinese Herbal Formula SiniZuojin Decoction in Treating GASTROINTESTINAL Ebb Ailment: Clinical Evidence and Potential Mechanisms; Front Pharmacol. 2020; 11:76. Doi: 10.3389/fphar.2020.00076. eCollection 2020.
2. Gan, Y. H. (2014). Clinical curative effect regarding sinisan and zuojinwan for the treatment regarding reflux esophagitis (RE). Chengdu Univ. Tradit. Chin. Med. Available online at: <http://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CMFD&dbname=CMFD201501&filename=1015543305.nh&uid>.
3. Gao, Q. D. (2017). The treatment regarding 36 cases regarding reflux esophagitis with zuojinwan and sinisan. J. Tradit. Chin. Med. 32 (13), 1893–1896. Doi: 10.3969/j.issn.1003-8914.2017.13.026
4. Gong, Y. Q. (2009). The clinical observation regarding Reflux 407 hinese 407 tio with the treatment regarding Sinisan and Zuojinwan. Hubei Coll. Tradit. Chin. Med.
5. Ahsan M, Rana ZA, Ali M, Anwer K, Assessment of knowledge, concerns and support of physicians *Ethiop. J. Health Dev.* 2021: 35(4)

- towards biobanks in Pakistan, and their willingness to donate, *SPR*, 2021;1(4): 320–328.
6. Hosseini, M., Salari, R., Shariatmaghani, S., Birjandi, B., and Salari, M. (2017). Gastrointestinal symptoms associated with gastrointestinal Ebb Ailment, and their relapses after treatment with proton pump inhibitors: a systematic review. *Electron. Physician* 9 (06), 4597–4605. Doi: 10.19082/4597
 7. Hosseinkhani, A., Lankarani, K. B., Mohagheghzadeh, A., Long, C., and Pasalar, M. (2018). An Evidence-based Review regarding Medicinal Herbs for the Treatment regarding gastrointestinal Ebb Ailment (Gastrointestinal ebb ailment). *Curr. Drug Discovery Technol.* 15 (04), 305–314.
 8. Hou, B. Y. (2016). The treatment regarding 50 cases regarding gastrointestinal Ebb Ailment by combination regardingsinisan, zuojinwan and rabeprazole. *Yunnan J. Tradit. Chin. Med. Materia Med.* 37 (03), 46–47. Doi: 10.16254/j.cnki.53-1120/r.2016.03.023
 9. Chu, M. Q. (2015). Clinical observation on the therapeutic effect regarding dredging the liver and lowering the stomach retrograde in the treatment regarding non-erosive GASTROINTESTINAL Ebb Ailment. *Nanjing Univ. Tradit. Chin. Med.* Available online at: http://www.wanfangdata.com.cn/details/detail.do?_type=degree&id=Y2875576.
 10. Dunbar, K. B., Agoston, A. T., Odze, R. D., Huo, X., Pham, T. H., CIPHER, D. J., et al. (2016). Association regarding acute GASTROINTESTINAL Ebb Ailment with esophageal histologic changes. *Jama* 315 (19), 2104–2112. Doi: 10.1001/jama.2016.5657
 11. Fan, Y. M. (2018). Effect regardingsinisan combined zuojin pill on reflux esophagitis. *World Latest Med. Inf. (Electronic Version)* 18 (93), 164–169. Doi: 10.19613/j.cnki.1671-3141.2018.93.138
 12. Hsu, C. S., Wang, C. C., Wang, P. C., Lin, H. H., Tseng, T. C., Chen, C. H., et al. (2010). Increased incidence regarding GASTROINTESTINAL Ebb Ailment in patients with chronic hepatitis B virus infection. *Hepatol. Int.* 4 (3), 585–593. Doi: 10.1007/s12072-010-9184-4
 13. Huang da, W., Sherman, B. T., and Lempicki, R. A. (2009). Bioinformatics enrichment tools: paths toward the comprehensive functional analysis regarding large gene lists. *Nucleic Acids Res.* 37 (1), 1–13. Doi: 10.1093/nar/gkn923
 14. Hunt, R., Armstrong, D., Katelaris, P., Afihene, M., Bane, A., Bhatia, S., et al. (2017). World gastroenterology 408 hinese 408 tion global guidelines: GASTROINTESTINAL Ebb Ailment global perspective on GASTROINTESTINAL Ebb Ailment. *J. Clin. Gastroenterol.* 51 (6), 467–478. Doi: 10.1097/mcg.0000000000000854
 15. Huo, H. Z., Wang, B., Liang, Y. K., Bao, Y. Y., and Gu, Y. (2011). Hepatoprotective and antioxidant effects regarding licorice extract against CCl₄-induced oxidative damage in rats. *Int. J. Mol. Sci.* 12 (10), 6529–6543. Doi: 10.3390/ijms12106529.
 16. Jia, Z. X., Lin, R. C., and Ma, Z. Q. (2017). Literature research on medicinal actions and clinical application sini regarding powder. *J. Liaoning Univ. Tradit. Chin. Med.* 19 (06), 159–162. Doi: 10.13194/j.issn.1673-842x.2017.06.049
 17. Kaminski-Hartenthaler, A., Gartlehner, G., Kien, C., Meerpohl, J. J., Langer, G., Perleth, M., et al. (2013). GRADE guidelines: 11. Making an overall rating regarding confidence in effect estimates for a single consequence and for all consequences. *Z. Evid. Fortbild Qual. Gesundheitswes* 107 (9-10), 638–645. Doi: 10.1016/j.zefq.2013.10.033
 18. Samaila B, Maidamma B, Usman B, Jega AI, Alhaji SA, Assessment of hazard index and incremental life cancer risk associated with heavy metals in the soils, *SPR*, 2021; 2(1): 340 – 360.
 19. Li, Q., Liu, F., Hou, Z., and Luo, D. (2013). Treatment regarding constipation- predominant irritable bowel syndrome by focusing on the liver in terms regarding Traditional Chinese Medicine: a meta-analysis. *J. Tradit. Chin. Med.* 33 (05), 562–571. Doi: 10.1016/S0254-6272(14)60022-4
 20. Lin, S., Li, H., and Fang, X. (2019). Esophageal motor dysfunctions in GASTROINTESTINAL Ebb Ailment and therapeutic perspectives. *J. Neurogastroenterol. Motil.* 25 (4), 499–507. Doi: 10.5056/jnm19081
 21. Parsel, S. M., Wu, E. L., Riley, C. A., and McCoul, E. D. (2019). GASTROINTESTINAL and laryngopharyngeal reflux associated with laryngeal malignancy: a systematic review and meta-analysis. *Clin. Gastroenterol. Hepatol.* 17 (07), 1253–1264.e1225 doi: 10.1016/j.cgh.2018.10.028
 22. Pasquereau, S., Kumar, A., and Herbein, G. (2017). Targeting TNF and TNF Receptor Pathway in HIV-1 Infection: from immune activation to viral reservoirs. *Viruses* 9 (4), 1–17. Doi: 10.3390/v9040064
 23. Picos, A., Badea, M. E., and Dumitrascu, D. L. (2018). Dental erosion in gastro- esophageal reflux disease. A systematic review. *Clujul Med.* 91 (04), 387–390. Doi: 10.15386/cjmed-1017
 24. Qin, X. G. (2015). A randomized control study regarding Sini powder combined with Zuojin pill in treating GASTROINTESTINAL Ebb Ailment regarding the type Disharmony Liver and Stomach. *Chin. J. New Drugs* 24 (11), 1275–1277, 1284.
 25. Shen, P., Zhang, Z., Zhu, K., Cao, H., Liu, J., Lu, X., et al. (2019). Evodiamine prevents dextran sulfate sodium-induced murine experimental colitis via the regulation regarding NF-kappaB and NLRP3 inflammasome. *BioMed. Pharmacother.* 110, 786–795. Doi: 10.1016/j.biopha.2018.12.033
 26. Shin, M. R., and Seo, B. I. (2017). Banhasasintang treatment reduces the severity regarding esophageal mucosal ulcer on chronic acid reflux esophagitis in rats. *BioMed. Res. Int.* 2017, 7157212. Doi: 10.1155/2017/7157212
 27. Tao, L., Xiao, Y., and Li, W. (2009). The treatment regarding 36 cases regarding gastrointestinal Ebb Ailment by sinisanzuojinwan

- and rabeprazole. *Beijing J. Tradit. Chin. Med.* 28 (10), 785–787. Doi: 10.16025/j.1674-1307.2009.10.028
28. Ling, W., Huang, Y., Xu, J. H., Li, Y., Huang, Y. M., Ling, H. B., et al. (2015). Consistent efficacy regarding wendan decoction for the treatment regarding digestive reflux disorders. *Am. J. Chin. Med.* 43 (05), 893–913. Doi: 10.1142/s0192415x15500524
 29. Liu, H., Wang, J., Zhou, W., Wang, Y., and Yang, L. (2013). Systems approaches and polypharmacology for drug discovery from herbal medicines: an example using licorice. *J. Ethnopharmacol.* 146 (3), 773–793. Doi: 10.1016/j.jep.2013.02.004
 30. Liu, W. W. (2007). The study on the compatibility regardingzhishi and baizhu and the mechanism regarding action regardingzhizhu yin in promoting stomach intestine dynamia. Heilongjiang Univ. *Chin. Med.*
 31. Muluye, R. A., Bian, Y., and Alemu, P. N. (2014). Anti-inflammatory and antimicrobial effects regarding heat-clearing 409hinese herbs: a current review. *J. Tradit. Complement. Med.* 4 (02), 93–98. Doi: 10.4103/2225-4110.126635
 32. Picos, A., Badea, M. E., and Dumitrascu, D. L. (2018). Dental erosion in gastro- esophageal reflux disease. A systematic review. *Clujul Med.* 91 (04), 387–390. Doi: 10.15386/cjmed-1017
 33. Teschke, R., Wolff, A., Frenzel, C., Eickhregardingf, A., and Schulze, J. (2015). Herbal traditional Chinese medicine and its evidence base in gastrointestinal disorders. *World J. Gastroenterol.* 21 (15), 4466–4490. Doi: 10.3748/wjg.v21.i15.4466
 34. Tominaga, K., and Arakawa, T. (2015). Clinical application regardingkampō medicine (rikkunshito) for common and/or intractable symptoms regarding the gastrointestinal tract. *Front. In Pharmacol.* 06 (07), 1–5. Doi: 10.3389/fphar.2015.00007
 35. Tourani, M., Habibzadeh, M., Karkhah, A., Shokri-Shirvani, J., Barari, L., and Nouri, H. R. (2018). Association regarding TNF-alpha but not IL-1beta levels with the presence regarding *Helicobacter pylori* infection increased the risk regarding peptic ulcer development. *Cytokine* 110, 232–236. Doi: 10.1016/j.cyto.2018.01.003
 36. Xu, F. L. (2006). The treatment regarding 50 cases regarding reflux esophagitis with zuojinwan and sinisan. *Shaanxi J. Tradit. Chin. Med.* 27 (01), 35–36. Doi: 10.3969/ j.issn.1000-7369.2006.01.021
 37. Zhu, H. L., and Fang, H. T. (2011). The treatment regarding 32 cases regarding non-erosiveastroesophageal reflux disease with liver-stomach heat retention by sinisan and zuojinwan. *J. Emergency Tradit. Chin. Med.* 20 (11), 1877. Doi: 10.3969/ j.issn.1004-745X.2011.11.101
 38. Wang, P. S., and He, L. (2018). Clinical efficacy and adverse reactions regardingJiaweiSiniZuojin Decoction in the treatment regarding reflux esophagitis with liver depression and spleen deficiency. *J. Clin. Med. Lit.* 05 (67), 174–175. Doi: 10.16281/ j.cnki.jocml.2018.67.097
 39. Wang, Z. G., Wu, J. M., Liu, J. J., Wang, L. Y., Lai, Y. G., Ibrahim, I. M., et al. (2009). Respiratory distress consequence Ing from GASTROINTESTINAL reflux is not asthma, but laryngotracheal irritation, spasm, even suffocation. *Chin. Med. Sci. J.* 24 (02), 130–132. Doi: 10.1016/s1001-9294(09)60076-6
 40. Wang, L., Wang, X., Zhang, S. L., Zhu, X. M., Liu, Y. Q., Song, Z. J., et al. (2017). Gastroprotective effect regarding palmitine against acetic acid-induced gastric ulcers in rats. *J. Nat. Med.* 71 (1), 257–264. Doi: 10.1007/s11418-016-1057-2
 41. Wetterslev, J., Jakobsen, J. C., and Gluud, C. (2017). Trial Sequential Analysis insystematic reviews with meta-analysis. *BMC Med. Res. Methodol.* 17 (1), 39. Doi: 10.1186/s12874-017-0315-7
 42. Xiao, J., and Yang, Y. (2018). Efficacy and safety regarding traditional 409 hinese medicine on nonerosive reflux disease: a meta-analysis regarding randomized controlled trials. *Evid. Based Complement. Alternat. Med.* 2018, 1505394. Doi: 10.1155/2018/1505394
 43. Yang, Y., Wang, S., Bao, Y. R., Li, T. J., Yang, G. L., Chang, X., et al. (2017). Anti-ulcer effect and potential mechanism regardinglicregardinglavone by regulating inflammation mediators and amino acid metabolism. *J. Ethnopharmacol.* 199, 175–182. Doi: 10.1016/ j.jep.2017.01.053
 44. Yu, G., Wang, W., Wang, X., Xu, M., Zhang, L., Ding, L., et al. (2018). Network pharmacology-based strategy to investigate medicinal mechanisms regardingZuojinwan for treatment regarding gastritis. *BMC Complement. Altern. Med.* 18 (01), 292. Doi: 10.1186/s12906-018-2356-9
 45. Yu, Y. (2005). Clinical study regarding treating reflux esophagitis with shu-gan-jiang-ni-tang. *Shandong Tradit. Chin. Med. Univ. Yuan.* G. H., Zhu, R. H., and Wang, Y. (2013). Effect observation regardingxuanfuxiexin hike decoction on GASTROINTESTINAL reflux cough. *J. Pract. Tradit. Chin. Med.* 29 (11), 898–899. Doi: 10.3969/ j.issn.1004-2814.2013.11.007
 46. Zhang, B. G., and Liu, Q. F. (2010). The new modern clinical application regarding zuojinwan. *Chin. Tradit. Patent Med.* 32 (08), 1408–1410. Doi: 10.3969/ j.issn.1001-1528.2010.08.037
 47. Travagli, R. A., and Anselmi, L. (2016). Vagal neurocircuitry and its influence on gastric motility. *Nat. Rev. Gastroenterol. Hepatol.* 13 (7), 389–401. Doi: 10.1038/ nrgastro.2016.76
 48. Zhang, S. S., Zhu, S. L., Wang, H. W., and Zhou, B. T. (2017). Consensus opinion on TCM diagnosis and treatment regardingGASTROINTESTINAL Ebb Ailment . *Chin. J. Integer. Trad. West Med. Dig.* 25 (05), 321–326. Doi: 10.3969/ j.issn.1671-038X.2017.05.01
 49. Zhou, W., Chen, Z., Wang, Y., Li, X., Lu, A., Sun, X., et al. (2019). Systems pharmacology-based method to assess the mechanism regarding action regarding weight-loss herbal intervention

- therapy for obesity. *Front. Pharmacol.* 10, 1165. Doi: 10.3389/fphar.2019.01165
50. Dai, Y., Zhang, Y., Li, D., Ye, J., Chen, W., and Hu, L. (2017). Efficacy and safety regarding modified banxiaxiexin decoction (pinellia decoction for draining the heart) for gastroesophageal reflux disease in adults: a systematic review and meta-analysis. *Evid. Based Complement. Alternat. Med.* 2017, 9591319. Doi: 10.1155/2017/9591319
51. Du, H. G., Ming, L., Chen, S. J., and Li, C. D. (2014). Xiaoyao pill for treatment regarding functional dyspepsia in perimenopausal women with depression. *World J. Gastroenterol.* 20 (44), 16739–16744. Doi: 10.3748/wjg.v20.i44.16739
52. Feng, Z. (2010). 32 cases regarding GASTROINTESTINAL Ebb Ailment treated with integrated Chinese and western medicine. *Pract. Clin. J. Integr. Tradit. Chin. Western Med.* 10 (03), 18–19. Doi: 10.3969/j.issn.1671-4040.2010.03.013
53. Asanuma, K., Iijima, K., and Shimosegawa, T. (2016). Gender difference in gastro- esophageal reflux diseases. *World J. Gastroenterol.* 22 (5), 1800–1810. Doi: 10.3748/wjg.v22.i5.1800
54. Naim A, Khan MF, Consumer behavior for health services: A psychological approach, *SPR*, 2021; 1(4): 298 – 309.
55. Deng CG, The dietary diversity and rural households' nutrition security in Itang special district, Gambella, Ethiopia, *SPR*, 2021;1(4): 258– 263.